id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-354168-omen8vvq	Al Saleh, Abdullah S.	Multiple Myeloma in the Time of COVID-19	2020-04-17		.txt	text/plain	3951	256	56	We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. For high-risk patients we recommend carfilzomib, lenalidomide, and dexamethasone (KRd) (preferred) or RVd. Decreasing the dose of dexamethasone to 20 mg and giving bortezomib subcutaneously once a week is recommended. We recommend delaying autologous stem cell transplant (ASCT), unless the patient has high-risk disease that is not responding well, or if the patient has plasma cell leukemia (PCL). If the patient cannot safely receive sulfa, we would recommend using prophylaxis other than pentamidine, as its administration requires a clinic visit and the fact that it is an aerosolized therapy could be a concern with the current COVID-19 pandemic. For standard-risk patients who are responding well to therapy, we would recommend delaying ASCT until the current situation with COVID-19 improves. Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment	./cache/cord-354168-omen8vvq.txt	./txt/cord-354168-omen8vvq.txt